Analysis of changes in the gut microbiome, and dosing of dopaminergic therapy under supplementation of short-chain fatty acids and prebiotics as dietary supplements in the context of PD - PRE-PD Study

BASF SE0 个研究点目标入组 80 人开始时间: 2021年11月19日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. age at PD: 18-90 years
•2. primary Parkinson's syndrome
•3. moderate disease severity (stable daily levodopa dose 500-850 mg daily)
•4. full orientation to time, place and person
•5. sufficient knowledge of German (able to give informed consent)
•6. independent mobility without, with unilateral or bilateral walking assistance

•1. poor general condition
•2. pregnancy
•3. severe concomitant disease or organ dysfunction (heart failure, NYHA stages III-IV, severe respiratory failure (e.g., with resting dyspnea), irreversible multiorgan failure, sepsis, acute viral hepatitis)
•4. serious previous diseases of the gastrointestinal tract
•5. malignancy (current or history with current follow-up/treatment)
•6. illness or medical treatment incompatible with study participation (pending surgical procedure, etc.)
•7. immunosuppressive therapy in the last 6 months (e.g. mitoxantrone, azathioprine, cyclophosphamide, MTX)
•8. intake of antibiotics or metformin during the past 3 months
•9. vegan dietary habits

发起方